Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.52 |
| ▸ | AGT | P01019 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9024777 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2AGTP2RX7AKT1 | |
| SCHEMBL30316147 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2AGTP2RX7AKT1 | |
| SCHEMBL9307853 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7HTT | |
| SCHEMBL13146764 | 0.87 | AGTR1 (0.55) | AGTR1AGTR2AGTHTTL3MBTL1 | |
| SCHEMBL29404889 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7HTT | |
| SCHEMBL796 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7HTT | |
| SCHEMBL8246839 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7HTT | |
| SCHEMBL4246354 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7AKT1 | |
| SCHEMBL8698703 | 0.86 | AGTR1 (0.47) | AGTR1AGTR2AGTHTTL3MBTL1 | |
| SCHEMBL8907583 | 0.85 | AGTR1 (0.51) | AGTR1AGTR2AGTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-0442473-B1 | Pyrimidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5162326-A | Antagonists for angeotensin; hypotensive agents; treatment for heart diseases, strokes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0442473-A1 | Pyrimidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | AGTR1 4/4885AGTR2 5/4885AGT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.